A joint study by researchers at the Indian Institute of Technology Kanpur (IIT Kanpur) and Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College has found that a combination of brain and gastric electrical signals, alongside clinical symptom data, can predict antidepressant treatment outcomes within just 7–10 days of starting therapy. The findings, published on Monday, 31 August, could significantly compress the conventional 4–6-week window currently required to assess whether a patient is responding to medication.

The Research and What It Examined

The study used electroencephalography (EEG) to measure electrical activity in the brain and electrogastrography (EGG) to record gastric electrical signals — both non-invasive techniques. Researchers enrolled 206 participants, including 144 treatment-naive patients diagnosed with depression. Signals were recorded at the start of treatment and again approximately one week later, and then cross-referenced against treatment outcomes assessed at the 4–6 week mark.

The study identified distinct patterns in brain and gut physiology that correlated with whether patients would respond to antidepressants — offering a biological basis for the wide variability seen in patient outcomes.

How Accurate Is the Predictive Model

The predictive model demonstrated 84% sensitivity and 78% specificity in identifying patients unlikely to respond to treatment during model evaluation. When tested on an independent patient cohort, it achieved 77.3% overall accuracy, with 80% specificity and 71.4% sensitivity for identifying non-responders. These figures suggest the approach is clinically meaningful, though researchers have not yet claimed it is ready for routine clinical deployment.

What the Researchers Said

'Our study showed that objective non-invasive brain and gut electrophysiological signals collected in about the first week of treatment already contain valuable information about treatment response to precisely guide the intervention,' said Dr. Pragathi Priyadharsini Balasubramani, Assistant Professor, Department of Cognitive Science, IIT Kanpur, and the study's corresponding author.

Amal Jude Ashwin Francis, PhD Scholar, Department of Cognitive Science, IIT Kanpur, and the study's first author, added: 'We found that different symptom profiles were associated with distinct patterns of brain and gut physiology linked to treatment outcomes.' Francis noted that recognising these biological subtypes helps explain why patients respond differently to the same medication and could enable more personalised treatment strategies.

Why This Matters for Depression Care in India

Depression affects an estimated 5% of adults globally and approximately 4.5% of India's population. Critically, more than half of all patients may not respond adequately to their first prescribed antidepressant — forcing clinicians into weeks of trial and error before landing on an effective regimen. This delay can worsen outcomes and increase the burden on both patients and the healthcare system.

This is the first study of its kind to combine EEG and EGG biomarkers with clinical data for early antidepressant response prediction, according to IIT Kanpur. The brain-gut axis — the bidirectional communication network between the central nervous system and the gastrointestinal tract — has attracted growing scientific attention, and this research adds a clinically actionable dimension to that body of work.

What Comes Next

The researchers indicated that the next steps would involve larger multi-centre trials to validate the model's accuracy across diverse patient populations. If replicated at scale, the approach could reshape how psychiatrists make early treatment decisions — potentially reducing the emotional and clinical cost of prolonged ineffective therapy.